Vireo Growth (VREOF) Treasury Shares (2022 - 2026)
Vireo Growth (VREOF) reported Treasury Shares of $59.6 million for Q1 2026, down 16.29% on a YoY basis from $71.2 million in Q1 2025, and up 425.84% sequentially from $11.3 million in Q4 2025.
Vireo Growth (VREOF) Treasury Shares (2022 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 5 years of Treasury Shares data on file, last reported at $59.6 million in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares fell 16.29% year-over-year to $59.6 million; the trailing twelve-month figure through Mar 2026 stood at $59.6 million (down 16.29% YoY), and the FY2025 full-year result was $11.3 million, changed 0.0% from the prior year.
- Treasury Shares climbed to $59.6 million in Q1 2026, from $11.3 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $73.2 million in Q3 2025 to a low of $1.1 million in Q1 2022.
- A 5-year average of $19.2 million and a median of $3.1 million in 2023 frame the typical range for Treasury Shares.
- Across the five-year window, Treasury Shares retreated 21.07% in 2023 and jumped 2782.87% in 2025, its largest moves.
- Tracing VREOF's Treasury Shares over 5 years: stood at $3.2 million in 2022, then declined by 21.07% to $2.5 million in 2023, then jumped by 345.44% to $11.3 million in 2024, then changed by 0.0% to $11.3 million in 2025, then soared by 425.84% to $59.6 million in 2026.
- Business Quant data shows VREOF's Treasury Shares at $59.6 million in Q1 2026, $11.3 million in Q4 2025, and $73.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 62.52 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 107.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.29 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 313.27 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.44 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 59.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.57 Mn |
| Mar 31, 2026 | 59.57 Mn |
| Dec 31, 2025 | 11.33 Mn |
| Dec 31, 2025 | 11.33 Mn |
| Sep 30, 2025 | 73.17 Mn |
| Sep 30, 2025 | 73.17 Mn |
| Jun 30, 2025 | 72.10 Mn |
| Jun 30, 2025 | 72.10 Mn |
| Mar 31, 2025 | 71.16 Mn |
| Mar 31, 2025 | 71.16 Mn |
| Dec 31, 2024 | 11.33 Mn |
| Dec 31, 2024 | 11.33 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 2.50 Mn |
| Mar 31, 2024 | 2.54 Mn |
| Mar 31, 2024 | 2.54 Mn |
| Dec 31, 2023 | 2.54 Mn |
| Dec 31, 2023 | 2.54 Mn |